Universal Nirsevimab Cuts Infant RSV Hospitalisations - European Medical Journal

Universal Nirsevimab Cuts Infant RSV Hospitalisations  European Medical JournalImpact of Nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective  FrontiersAnalysis suggests nirsevimab cuts infant RSV hospitalizations 83%  CIDRAPNew Data Show Beyfortus Protects All Infants From Severe RSV  Infectious Disease Special EditionNirsevimab Lowers RSV Hospitalizations More Than Maternal Vaccination: JAMA  Medical Dialogues